Business Context and Reporting Period
Company: Omeros Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: January 22, 2013
Event: Announcement of safety data from the second Phase 3 clinical trial for OMS302 in patients undergoing intraocular lens replacement surgery.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a clinical trial update.
Material Changes
No material financial changes are reported. The material event is the release of safety data regarding the OMS302 clinical trial, which is incorporated by reference via an attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release detailing safety data but does not include specific management commentary, forward-looking guidance, or risk factors within the text of the 8-K itself.
Unusual Items: None reported in this specific filing text.
Key Facts for Investor Verification
- Verify the full content of the press release (Exhibit 99.1) for specific safety data details regarding OMS302.
- Confirm the status of the Phase 3 clinical trial for intraocular lens replacement surgery.
- Note that this filing contains no financial performance data; refer to recent 10-Q or 10-K filings for financial metrics.